Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC

Prior treatment

• Participation in another interventional drug clinical trial within 4 weeks prior to enrollment.
• Prior systemic anti-tumor therapy with anti-angiogenic agents.
• Prior treatment with TROP2-targeted therapies and/or topoisomerase I inhibitors.
• Known hypersensitivity or allergy to any investigational product or its components.
• Receipt of live vaccines within 30 days prior to the first dose of study treatment.
• Pulmonary embolism within 3 months prior to first dose
• Prior pneumonectomy
• Active infection requiring systemic therapy within 2 weeks prior to the first dose of study treatment.
• Serious concomitant diseases that, in the investigator's judgment, may compromise patient safety or interfere with completion of the study, including but not limited to uncontrolled hypertension, severe diabetes mellitus, or active infection.

Other illness

• History of other malignancies within the past 5 years, except for adequately treated cervical carcinoma in situ, basal cell carcinoma of the skin, or squamous cell carcinoma of the skin.
• Known positive human immunodeficiency virus (HIV) infection, history of acquired immunodeficiency syndrome (AIDS), or known active syphilis infection.
• History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
• History of interstitial lung disease (ILD) or non-infectious pneumonitis requiring steroid treatment; current ILD or non-infectious pneumonitis; or suspected ILD or non-infectious pneumonitis that cannot be excluded by imaging at screening. Severe pulmonary impairment due to pulmonary comorbidities, including but not limited to:
• Severe chronic obstructive pulmonary disease
• Restrictive lung disease
• Autoimmune, connective tissue, or inflammatory diseases involving the lungs (e.g., rheumatoid arthritis, Sjögren's syndrome, sarcoidosis)
• Active autoimmune disease requiring systemic treatment within the past 2 years (hormone replacement therapy is not considered systemic treatment, such as type 1 diabetes mellitus, hypothyroidism requiring only thyroid hormone replacement, or adrenal or pituitary insufficiency requiring physiologic doses of corticosteroids).
• Documented severe dry eye syndrome, severe meibomian gland dysfunction and/or blepharitis, or a history of corneal disorders that may interfere with delayed corneal healing.
• Any other condition that, in the investigator's opinion, makes the patient unsuitable for participation in the study.

Other

• Tumors with a high risk of massive hemoptysis, as judged by the investigator.
• Severe asthma
• Pleural effusion
• Pregnant or breastfeeding women; women of childbearing potential with a positive baseline pregnancy test; or women of childbearing potential who are unwilling to use effective contraception during study treatment and for 6 months after the last dose of study treatment.

• Age ≥18 years at the time of signing informed consent; male or female.
• Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC).
• Disease progression after receiving only one prior line of therapy consisting of a PD-(L)1 inhibitor combined with platinum-based doublet chemotherapy.
• At least one measurable target lesion per RECIST v1.1 as assessed by the investigator, which has not been previously irradiated.
• Patients with asymptomatic brain metastases, or patients with treated brain metastases and stable symptoms for ≥4 weeks, are eligible.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Estimated life expectancy of at least 12 weeks.
• Adequate organ and bone marrow function (no blood transfusion, recombinant human thrombopoietin, or colony-stimulating factors within 2 weeks prior to first dose), defined as follows:
• Hematologic function:
• Absolute neutrophil count ≥1.5 × 10⁹/L
• Platelet count ≥100 × 10⁹/L
• Hemoglobin ≥90 g/L
• Hepatic function:
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN; for patients with liver metastases, AST and ALT ≤5 × ULN
• Albumin ≥30 g/L
• Total bilirubin ≤1.5 × ULN
• Renal function:
• Creatinine clearance ≥50 mL/min, calculated using the Cockcroft-Gault formula
• Coagulation function:
• International normalized ratio (INR), activated partial thromboplastin time (APTT), and prothrombin time (PT) ≤1.5 × ULN
• Women of childbearing potential and men with partners of childbearing potential must agree to use effective medical contraception from signing informed consent until 6 months after the last dose of study treatment.
• Subjects must voluntarily participate in the study, provide written informed consent, and be able to comply with protocol-required visits and study procedures.